Gene Therapy Analytical Development 2023
Behind regulatory milestones like the recent accelerated FDA approval for Duchenne Muscular Dystrophy, robust and detailed analytics are the cornerstone of gene therapy development. As regulators scrutinize products more closely, accurately characterizing gene therapy products and standing behind safety and efficacy is crucial to drug developers bringing gene therapies into and through the clinic.
Time: 8:00 AM – 5:00 PM
Venue details: Boston Park Plaza, 50 Park Plaza, Boston, Massachusetts, 02116, United States
Prices: USD 3199.00 – USD 6195.00
Speakers: Adam Washburn, Director, Research and Development, Eli Lilly, Akshata Ijantkar, Senior Principal Scientist and CMC Team Lead, Gene and Cell Therapy Programs, Bristol Myers Squibb, Allison Schorzman, Scientist II, BridgeBio Gene Therapy, and more
Event Organizer - Hanson Wade
